Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication

被引:0
作者
Tek N. Lamichhane
Anjana Jeyaram
Divya B. Patel
Babita Parajuli
Natalie K. Livingston
Navein Arumugasaamy
John S. Schardt
Steven M. Jay
机构
[1] University of Maryland,Fischell Department of Bioengineering
[2] University of Maryland,Program in Oncology, Marlene and Stewart Greenebaum Cancer Center
[3] University of Maryland,Program in Molecular and Cell Biology
来源
Cellular and Molecular Bioengineering | 2016年 / 9卷
关键词
Exosomes; siRNA delivery; microRNA; HER2; Cancer nanoparticle; Nanobiotechnology; Biotherapeutic; Biopharmaceutical;
D O I
暂无
中图分类号
学科分类号
摘要
Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as promising drug delivery vehicles for small RNAs (siRNA and miRNA) due to their natural role in intercellular RNA transport. However, the application of EVs for therapeutic RNA delivery may be limited by loading approaches that can induce cargo aggregation or degradation. Here, we report the use of sonication as a means to actively load functional small RNAs into EVs. Conditions under which EVs could be loaded with small RNAs with minimal detectable aggregation were identified, and EVs loaded with therapeutic siRNA via sonication were observed to be taken up by recipient cells and capable of target mRNA knockdown leading to reduced protein expression. This system was ultimately applied to reduce expression of HER2, an oncogenic receptor tyrosine kinase that critically mediates breast cancer development and progression, and could be extended to other therapeutic targets. These results define important parameters informing the application of sonication as a small RNA loading method for EVs and demonstrate the potential utility of this approach for versatile cancer therapy.
引用
收藏
页码:315 / 324
页数:9
相关论文
共 237 条
  • [1] Alvarez-Erviti L(2011)Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat. Biotechnol. 29 341-345
  • [2] Seow Y(2013)Extracellular vesicles: biology and emerging therapeutic opportunities Nat. Rev. Drug Discov. 12 347-357
  • [3] Yin H(2012)Treatment of HER2-positive breast cancer: current status and future perspectives Nat. Rev. Clin. Oncol. 9 16-32
  • [4] Betts C(2009)Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat. Rev. Cancer. 9 463-475
  • [5] Lakhal S(2007)miRNAs in cancer: approaches, aetiology, diagnostics and therapy Hum. Mol. Genet. 16 R106-R113
  • [6] Wood MJ(2006)RNAi therapeutics: a potential new class of pharmaceutical drugs Nat. Chem. Biol. 2 711-719
  • [7] Andaloussi EL(2004)Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines Int. J. Cancer. 108 71-77
  • [8] Mager I(2013)Safety and efficacy of RNAi therapy for transthyretin amyloidosis N. Engl. J. Med. 369 819-829
  • [9] Breakefield XO(2014)Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice Mov. Disord. 29 1476-1485
  • [10] Wood MJ(2008)Drug delivery and nanoparticles: applications and hazards Int. J. Nanomed. 3 133-149